Cheng Chi Fung 4
Research Summary
AI-generated summary
Credo (CRDO) CTO Cheng Chi Fung Sells 31,290 Shares
What Happened
Cheng Chi Fung, Credo Technology Group Holding Ltd (CRDO) Chief Technology Officer and director, sold a total of 31,290 shares in open-market/private sales on July 7–8, 2026 for aggregate proceeds of approximately $7.66 million. The trades were executed in multiple lots (examples: 3,085 shares at $237.60 for $733,000; 3,275 shares at $241.62 for $791,310; 3,790 shares at $258.71 for $980,511). Prices on the reported trades ranged roughly from $236.58 up to $258.71.
Key Details
- Transaction type: Sale (S) — total 31,290 shares sold for ≈ $7,664,770.
- Transaction dates: primarily 2026-07-07, with additional sales on 2026-07-08; filing date 2026-07-09 (Form 4 filed within the normal 2-business-day window).
- Price range: reported weighted-average prices per lot between $236.58 and $258.71; several lots were executed in multiple trades with price ranges noted in footnotes (see F2–F18).
- Ownership/Trust: Shares sold were held by the Cheng Huang Family Trust (Cheng and spouse are trustees; reporting person disclaims beneficial ownership except for pecuniary interest) (footnote F3).
- 10b5-1 plan: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Cheng Huang Family Trust on Sept 5, 2025 (footnote F1).
- Trade detail availability: Many lots were executed in multiple trades and the filing reports weighted-average prices; the reporting person offers to provide full trade-level details upon request (per footnotes).
- Shares owned after transaction: Not specified in the summary provided here—see the full Form 4 for the reporting person’s post-transaction holdings.
Context
- These are outright sales (routine liquidity) executed under a pre-established 10b5-1 plan, which typically indicates the trades were scheduled in advance rather than timed to inside information.
- For retail investors, sales are less informative than purchases about insider sentiment; note the trust/10b5-1 structure and the trustee/beneficial-ownership disclaimer when assessing significance.